2025. Long-Term Durability and Stability of Amlitelimab Efficacy in Adults With Moderate-to-Severe Atopic Dermatitis: 52-Week Post Hoc Analysis of the STREAM-AD Phase 2b Trial. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s607. DOI:https://doi.org/10.25251/qx64pd52.